Follicular Lymphoma 2016:
|
|
- Darlene Golden
- 5 years ago
- Views:
Transcription
1 Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB
2 Disclosures I have no actual or potential conflict of interest in relation to this presentation Honoraria: Pfizer, Boehringer-Ingelheim, Astra-Zeneca, Roche, Lundbeck, Eli-Lilly, Bristol-Myers Squibb, Merck Advisory Boards: Boehringer-Ingelheim, Astra-Zeneca, Roche, Eli-Lilly, Bristol-Myers Squibb, Merck, Novartis
3 Outline 1. Non-Hodgkin Lymphoma Epidemiology 2. Follicular Lymphoma Pathobiology 3. First-line Management of Follicular Lymphoma 4. Treating Relapsed/Refractory Follicular Lymphoma 5. Investigational Agents in Relapsed/Refractory Follicular Lymphoma
4 Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma (NHL) Heterogeneous group of > 40 lymphoproliferative malignancies Result from clonal expansion of B- or T- or NK-cells Variable patterns of behavior and response to treatment In 2015, 6 th most common cancer in Canada 8200 diagnosed 2700 die age adjusted incidence/100,000/yr Year lung colorectal breast NHL Hodgkin lymphoma Canadian Cancer Statistics 2016
5 NHL: Subtype Frequency Follicular lymphoma Most common indolent (low-grade) NHL and considered incurable
6 Question 1 A 50 year old male hematologist with no significant comorbidities is diagnosed with Stage IIIA NHL. The pathology subtype remains pending. Which of the following subtypes do you believe he would prefer to have? A. Follicular lymphoma, grade I-II B. Diffuselarge B-cell lymphoma C. Peripheral T-cell lymphoma, NOS D. Burkitt Lymphoma
7 Pathobiology of Follicular Lymphoma (FL) Common Mutational Alterations: t(14;18) in 85% of FL and inactivating mutations of MLL2 in >80% of FL Roulland et al, J Exp Med, 2006 Kahl and Yang, Blood, 2016
8 FL Microenvironment Kahl and Yang, Blood, 2016
9 Prognosis FLIPI FLIPI-2 Solal-Celigny et al, Blood, 2004 Federico et al, JCO, 2009
10 Prognosis: m7-flipi m7-flipi Integration of mutational status of 7 genes (EZH2, ARID1A, MEF2B, EP300, FOX01, CREBBP, and CARD11) with FLIPI Superior at identifying high-risk population compared to FLIPI alone (5-yr FFS of 25% vs 46%, respectively) Requires prospective validation Pastore et. al., Lancet Oncol, 2015
11 FL Overarching Management Principles 1. Disease has a long, incurable, remitting/relapsing natural history so several treatment approaches are reasonable 2. Mere presence of disease along does not imply need for treatment
12 Alberta Treatment Algorithm Alberta Lymphoma Clinical Practice Guideline, Version 10
13 Watch & Wait vs Early Treatment Era Before Rituximab No survival advantage to starting therapy early Rituximab Era Young RC, Longo DL, Glatstein E, et al. Semin Hematol 1988;25:11-6 Brice P, Bastion Y, Lepage E, et al. J Clin Oncol 1997;15: Ardeshna KM, Smith P, Norton A, et al. Lancet 2003;362: Ardeshna et. al., Lancet Oncol, 2014 Kuruvilla et al, Clin Lymphoma, Myeloma, and Leukemia, 2015
14 Alberta Treatment Algorithm Alberta Lymphoma Clinical Practice Guideline, Version 10
15 FOLL05: Study Design Federico et. al., JCO, 2013
16 FOLL05: Time to Treatment Failure Federico et. al., JCO, 2013
17 StiL NHL : Phase III Non-Inferiority Trial N=549 (FL with BR = 139 pts; FL with R-CHOP = 140 pts) No maintenance or consolidation treatment allowed Rummel et. al., The Lancet, 2013
18 StiL NHL : PFS Rummel et. al., The Lancet, 2013 Median F/U: 45 mo
19 StiL NHL : PFS for FL Rummel et. al., The Lancet, 2013
20 StiL NHL : TTNT Median F/U: 87 mo Median TTNT not reached in BR group and 42.3 mo in R-CHOP group Rummel et. al., ASH 2014; Abs 4407
21 StiL NHL : Overall Survival in FL Rummel et. al., ASH 2014; Abs 4407
22 First-Line Treatment for FL Based on the StiL and confirmatory BRIGHT study, the recommended chemoimmunotherapy for first-line symptomatic advanced stage FL is Rituximab + Bendamustine for a total of 6 cycles.
23 PRIMA: Maintenance R after 1 st -Line Treatment of FL Primary Endpoint: PFS
24 PRIMA: Results UPDATED 6-year PFS: 60% vs 42% (p <.0001) Salles et. al., Lancet, 2011 Salles et al., ASH 2013, abstr 509
25 StiL NHL MAINTAIN Trial: Study Design
26 Relapsed/Refractory Follicular Lymphoma
27 Response Duration with Consecutive Treatments in FL Johnson et. al., JCO, 1995
28 Relapse within 2-yrs Associated with Poor Outcome National LymphoCare study 588 patients with R-CHOP as 1 st line therapy 20% with progressive disease within 2 years of diagnosis (early-pd) 5-yr OS of 50% compared to 5-yr OS of 90% without early-pd Casulo et. al., JCO, 2015
29 Question 2 A 55 year old female with Stage IVA follicular lymphoma, FLIPI 3, was treated with 6 cycles of R-bendamustine and achieved a CR. Approximately, 15 months later, new symptomatic, supra- and subdiaphragmatic lymphadenopathy was confirmed on CT imaging. Repeat biopsy showed follicular lymphoma without evidence of transformation. Whattreatment wouldyou recommend? A. Watch and Wait B. R-Bendamustine re-challenge C. R-CHOP D. HDCT and Autologous Stem-Cell Transplant (ASCT) E. Compassionate Access of a New Targeted Therapy F. Allogeneic Stem-Cell Transplant
30 Approach to R/R FL Kahl and Yang, Blood, 2016
31 CUP Trial: Improved Survival wit ASCT for R/R FL P F S 2-yr PFS for C (26%); U (58%); P(55%) 4-yr OS for C (46%); U (71%); P (77%) Schouten et. al., JCO, 2003
32 Durable EFS with ASCT in R/R FL 100 consecutive patients in Calgary 25 primary refractory, 29 in 2 relapse, and 24 transformed Post-ASCT, 5-year EFS and OS rates 56% and 70%, respectively Peters et. al., Leuk Lymph, 2011
33 Bendamustine for Rituximab Refractory FL Rituximab-refractory = no response or PD within 6 months of receiving rituximab (single-agent, maintenance, or with chemo) Phase II multicenter trial; N=100 with 62 pts FL ORR 75% (14% CR, 3%Cru); DOR 9.2 mo; PFS 9.3 mo Kahl et al, Cancer, 2010
34 GADOLIN: Phase III Trial in Rituximab Refractory Indolent NHL Kahl et al, Lancet Oncol, 2016
35 GADOLIN: IRF-assessed PFS Kahl et al, Lancet Oncol 2016
36 GADOLIN: PFS by Sub-group Kahl et al, Lancet Oncol, 2016
37 Question 3 A 74 year old male with follicular lymphoma, FLIPI 2, has been treated over the past decade with R-CVP x 8 cycles (CR ~ 5 years), R- bendamustine x 6 cycles with maintenance Rituximab (CR ~ 3 years). He has undergone radiotherapy for a bothersome left axillary lymph node but now presents with more widespread symptomatic lymphadenopathy (no evidence of transformation). What do you recommend? A. R-CVP B. R-CHOP C. Ibrutinib D. Lenalidomide E. Idelalisib F. Anti-PD-1/PD-L1 therapy G. None of the above
38 Investigational Agents in Relapsed/Refractory Follicular Lymphoma
39 CALGB 50401: Lenalidomide Randomized Trial of Lenalidomide Alone Versus Lenolidamide Plus Rituximab in Patients with Recurrent Follicular Lymphoma Leonard et al, JCO 2014
40 CALGB 50401: Response and TTP Lenalidomide active as monotherapy and improved in combination with rituximab Gr 3 toxicities 58% vs 53%; Gr 3 ANC 16% vs 20%, L and LR respectively 36% of L vs 63% of LR completed 12 cycles. Leonard et al, JCO 2014
41 Lenalidomide Trials RELEVANCE: Phase III open-label randomized study to compare efficacy and safety of LR versus chemotherapy + R in previously untreated FL AUGMENT: Phase III double-blind, randomized study to compare the efficacy and safety of of LR versus R plus placebo in R/R indolent lymphoma ALLIANCE Phase I study of LR + Ibrutinib in previously untreated FL
42 DELTA Trial: Idelalisib (PI3Kδ Inhibitor) Phase II Trial (N=125; FL=72); Primary Endpoint of ORR Received 2 lines of therapy and refractory to both R and Alkylating Agent Median prior treatments = 4 (Range 2 to 12) Gopal et al, NEJM 2014 Median DOR 12.5 mo; PFS 11 mo
43 Polatuzumab Vedotin: ADC against CD79b
44 ROMULUS Phase II Trial Morschhauser et al, ASCO 2014 N=20 for FL; ORR 70%; CR 40%
45 Investigational Agents in Relapsed FL Kahl and Yang, Blood 2016
46
47 The Concept of Value
48 Back to Outline 1. Non-Hodgkin Lymphoma Epidemiology 2. Follicular Lymphoma Pathobiology 3. First-line Management of Follicular Lymphoma 4. Treating Relapsed/Refractory Follicular Lymphoma 5. Investigational Agents in Relapsed/Refractory Follicular Lymphoma
49 Thank You Enjoy CHC-WEST 2016!
Follicular Lymphoma. Michele Ghielmini. Oncology Institute of Southern Switzerland Bellinzona
Follicular Lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona Conflicts of interest Astra Zeneca Roche Cellgene Mundipharma Janssen Gilead Bayer Abbvie FL remains an incurable
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationEmerging targeted therapies for follicular lymphoma A future without chemotherapy
Emerging targeted therapies for follicular lymphoma A future without chemotherapy Pier Luigi Zinzani Institute of Hematology L. e A. Seràgnoli University of Bologna FOLLICULAR LYMPHOMA: GENERAL ASPECTS
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationChallenges in the Treatment of Follicular Lymphoma
Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationIl trattamento del Linfoma Follicolare in prima linea
Il trattamento del Linfoma Follicolare in prima linea Dr.ssa Carola Boccomini SC Ematologia Dr. U. Vitolo AO Città della Salute e della Scienza Torino, Italy Median follow-up 3 years Median follow-up 6
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationHow I treat High-risk follicular lymphoma
How I treat High-risk follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona 1) median OS raised from 10 to 18 y 2) advanced FL remains uncurable Stanford, n = 1334
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationPOST ICML Indolent lymphomas relapse treatment
POST ICML Indolent lymphomas relapse treatment Georg Hess University Medical School Johannes Gutenberg-University Mainz, Germany Treatment of relapsed indolent lymphoma 2 General categories of second line
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationPanel Discussion/References
Follicular Lymphoma (FOLL) Panel discussion to reassess the category designation for lenalidomide + rituximab as a firstline therapy for FL. Panel discussion to reassess the inclusion of radioimmunotherapy
More informationLymphoma- Med A-new drugs and treatments
Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationUpdates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics
Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationU.S. Management of First Relapse Follicular Lymphoma
U.S. Management of First Relapse Follicular Lymphoma Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C., USA FLASH Analysis Dataset The current analyses
More informationOptions in Mantle Cell Lymphoma Therapy
Options in Mantle Cell Lymphoma Therapy Carlo Visco, MD Dept of Cell Therapy and Hematology San Bortolo Hospital, Vicenza, taly My Disclosures: ADVSOR OR ADVSORY BOARDS: Lundbeck Canada nc, Celgene Europe,
More informationBendamustine: A Transversal * Chemotherapy Agent
Bendamustine: A Transversal * Chemotherapy Agent Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C., USA *Def Cutting across two lines, intersecting
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationLow grade Non-Hodgkin Lymphoma: New Therapies & Updates
Low grade Non-Hodgkin Lymphoma: New Therapies & Updates Craig A. Portell MD Assistant Professor of Medicine ivision of Hematology/Oncology University of Virginia Friday, April 28, 2017 Disclosures I have
More informationPanel Discussion/References
Follicular Lymphoma (FOLL) FOLL-B category designation for first-line therapy options for FL: Bendamustine + rituximab RCHOP RCVP Submission from Genentech to review the data related to obinutuzumab for
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationTransformed lymphoma: biology and treatment
Transformed lymphoma: biology and treatment Silvia Montoto Centre for Haemato-Oncology Barts Cancer Institute 1.00 0.75 0.50 0.25 0.00 N =330 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Years %Viability
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationRecent Advances in the Treatment of Non-Hodgkin s Lymphomas
671 Highlights of the NCCN 18th Annual Conference Recent Advances in the Treatment of Presented by Jeremy S. Abramson, MD, and Andrew D. Zelenetz, MD, PhD Abstract Non-Hodgkin s lymphomas (NHL) represent
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationUNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL. June 6, 2018
UNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL June 6, 2018 0 PRESENTATION OVERVIEW IN CLL/SLL AND FL: Review patient heterogeneity and its connection to unmet needs Explore unmet needs within the CLL/SLL
More informationHow to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma
How to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma Peter A. Riedell, MD and Brad S. Kahl, MD Abstract Follicular lymphoma (FL) is the most common
More informationOverview of Lymphoma Clinical Trials
Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants
More informationTransformed follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
Transformed follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. The past: Incidence and Outcome of Transformed NHL Steady risk of 3% per year for first 15 years of diagnosis Treatment (or lack thereof)
More informationCME Information. Y-ibritumomab tiuxetan to that of rituximab maintenance for patients with newly diagnosed follicular lymphoma (FL).
CME Information LEARNING OBJECTIVES Compare the efficacy of consolidation therapy with a single dose of 90 Y-ibritumomab tiuxetan to that of rituximab maintenance for patients with newly diagnosed follicular
More informationTherapeutic targeting of microenvironment in follicular lymphoma
INDOLENT LYMPHOMA:MICROENVIRONMENT Therapeutic targeting of microenvironment in follicular lymphoma Grzegorz S. Nowakowski 1 and Stephen M. Ansell 1 1 Mayo Clinic, Rochester, MN Immune and nonimmune microenvironmental
More informationTreatment Nodal Marginal Zone Lymphoma
Workshop : Indolent lymphomas Treatment Nodal Marginal Zone Lymphoma Catherine Thieblemont Hôpital Saint-Louis, Paris - France Bologna 16th, 2017 Ø No standardized treatment Ø Similarly treated as FL Treatment
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationChoice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma
Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationTraditional Therapies for Waldenstrom s Macroglobulinemia. Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014
Traditional Therapies for Waldenstrom s Macroglobulinemia Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014 Jeff Atlin (1953-2014) Standard treatment options Single drug therapies
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationNovel treatment options for Waldenstrom Macroglobulinemia
Novel treatment options for Waldenstrom Macroglobulinemia Irene Ghobrial, MD Associate Professor of Medicine Harvard Medical School Dana Farber Cancer Institute Boston, MA Ghobrial et al, Lancet Oncol
More informationRichter s Syndrome: Risk, Predictors and Treatment
Richter s Syndrome: Risk, Predictors and Treatment 10/23/2015 John N. Allan MD Assistant Professor of Medicine Division of Hematology and Medical Oncology CLL Research Center Weill Cornell Medicine Agenda
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationeastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning
Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Reference: NHS England 1607 1 First published: TBC Prepared by NHS England
More informationA CME-certified Oncology Exchange Program
A CME-certified Oncology Exchange Program Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Seattle Genetics, Inc. Re-treatment with BV Bartlett
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationLymphoma John P. Leonard, M.D.
Lymphoma 2017 John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department of Medicine Disclosures Consulting
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationOutcomes of Treatment in Slovene Follicular Lymphoma Patients
Original Study Outcomes of Treatment in Slovene Follicular Lymphoma Patients Tanja Juznic Setina, Simona Borstnar, Barbara Jezersek Novakovic Abstract The treatment outcomes of follicular lymphoma (FL)
More informationAngioimmunoblastic T-cell lymphoma: nobody knows what to do...
Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Felicitas Hitz, Onkologie/Hämatologie St.Gallen SAMO Lucerne 17.9.2011 : Problems PTCL are rare diseases with even rarer subgroups Difficulte
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationIndolent Lymphomas and Hodgkin Lymphoma: Achieving Curability
Indolent Lymphomas and Hodgkin Lymphoma: Achieving Curability Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C. Di$clo$ure$ Consulting & advisory
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationCheckpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD
Checkpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD Disclosures for Rob Laister Research Support Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bendamustine (Treanda) for Non-Hodgkin Lymphoma November 29, 2012
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bendamustine (Treanda) for Non-Hodgkin Lymphoma November 29, 2012 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationClinical Advances in Lymphoma
Conflicts of Interest Clinical Advances in Lymphoma Alex F. Herrera, MD Assistant t Professor Department of Hematology and HCT City of Hope BMS research funding (institutional), consultancy Genentech research
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationNHS England. Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
More informationClinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages)
Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: 170029P 1 NHS England INFORMATION READER BOX Directorate Medical
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma. Reference: NHS England 1630
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma Reference: NHS England 1630 1 First published: TBC Prepared by NHS England Specialised
More informationThe role of rituximab for maintenance therapy in
COUNTERPOINTS Current Controversies in Hematology and Oncology Counterpoints Is Maintenance Therapy Necessary in Low-Grade Lymphoma? Maintenance therapy with rituximab has been shown to prolong progression-free
More information